☆ 4.2 Review

Clinical Updates for Colon Cancer Care in 2022

CLINICAL COLORECTAL CANCER (2022)

Related references

Note: Only part of the references are listed.

Meeting Abstract Oncology

Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Heinz-Josef Lenz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials

Claire Gallois et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

BREAKWATER: Randomized phase 3 study of encorafenib (enco) plus cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC)

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan

Masahito Kotaka et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Marla Lipsyc-Sharf et al.

Summary: This study found no significant differences in survival rates between young-onset colorectal cancer (yoCRC) patients and older patients with metastatic colorectal cancer (mCRC).

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

K. Yamazaki et al.

Summary: The study showed that a 3-month combination therapy had significantly less grade >= 2 PSN compared to the 6-month regimen. Shortening the therapy duration did not affect the 3-year DFS rate, indicating that a 3-month course of CAPDX can be an effective treatment option.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer

Kai-Keen Shiu et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

Valerie Boige et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).

John H. Strickler et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.

Yihebali Chi et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

Francois Quenet et al.

Summary: This study aimed to evaluate the specific benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery compared with receiving cytoreductive surgery alone in patients with colorectal peritoneal metastases. The results showed no significant overall survival benefit after adding HIPEC, with more frequent postoperative late complications, suggesting that cytoreductive surgery alone should be prioritized as a treatment strategy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero et al.

Summary: The study evaluated different treatment regimens for patients with BRAF V600E-mutant metastatic colorectal cancer, showing that encorafenib plus cetuximab improved overall survival, objective response rate, and progression-free survival compared to standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer

Arvind Dasari et al.

Summary: Fruquintinib, a novel tyrosine kinase inhibitor, is approved in China for metastatic colorectal cancer treatment. The global FRESCO-2 study aims to assess its efficacy and safety in refractory patients.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial

Jeffrey A. Meyerhardt et al.

Summary: Adding celecoxib to standard adjuvant chemotherapy did not significantly improve disease-free survival among patients with stage III colon cancer. This study investigated the impact of adding celecoxib to standard adjuvant chemotherapy on disease-free survival in patients treated for stage III colon cancer.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Medicine, General & Internal

Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Jennifer S. Lin et al.

Summary: There are multiple screening options for colorectal cancer, each with varying levels of evidence in reducing cancer mortality, detecting cancer or precursor lesions, and risks of harms. This systematic review summarizes published evidence on the benefits and harms of screening for colorectal cancer in asymptomatic, community-dwelling adults to support the 2021 US Preventive Services Task Force Recommendation Statement.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Medicine, General & Internal

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement

Karina W. Davidson et al.

Summary: Colorectal cancer is a significant cause of cancer-related deaths, with high incidence in adults aged 65 to 74. Screening is recommended for adults aged 50 to 75 with substantial net benefit, for those aged 45 to 49 with moderate net benefit, and selective screening is advised for adults aged 76 to 85.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Thierry Andre et al.

Summary: The KEYNOTE-177 study found that pembrolizumab monotherapy significantly improved progression-free survival in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer compared to chemotherapy as first-line treatment, with clinically meaningful benefits. Health-related quality of life analyses further supported these findings.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena et al.

Summary: This study aimed to investigate the antitumour activity and safety of trastuzurnab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. The drug showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with previous trials. However, careful monitoring and prompt intervention are required for important risks like interstitial lung disease and pneumonitis.

LANCET ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

T. Andre et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

V. Boige et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Richard A. Adams et al.

Summary: Despite strong evidence of disease control with maintenance therapy, overall survival (OS) remains unaffected. The FOCUS4-N trial demonstrated significant efficacy in progression-free survival (PFS) with maintenance capecitabine therapy, but no significant improvement in OS. Toxicity between the capecitabine and active monitoring groups was comparable, with expected side effects such as fatigue, diarrhea, and hand-foot syndrome.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database

Zhaohui Jin et al.

Summary: The study revealed that tumor biology is a more significant prognostic factor than age of onset in predicting the outcome of stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Oncology

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Yihebali Chi et al.

Summary: In summary, the study showed that treatment with Anlotinib significantly prolonged progression-free survival in patients with refractory metastatic colorectal cancer, with improvements in objective response rate and disease control rate. However, overall survival was similar between the two groups.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Colorectal cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Oncology

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial

Fausto Petrelli et al.

JAMA ONCOLOGY (2020)

Add to Collection

Letter Oncology

Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer

Zhengyi Zhao et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

Federica Tosi et al.

CLINICAL COLORECTAL CANCER (2020)

Add to Collection

Review Medicine, General & Internal

Colorectal cancer

Evelien Dekker et al.

LANCET (2019)

Add to Collection

Review Oncology

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

S. Siena et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

A. Grothey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Meeting Abstract Oncology

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer (mCRC) patients by tumor location.

Lauren C. Bylsma et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Editorial Material Oncology

Colorectal cancer: a disease of the young?

[Anonymous]

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

Manish A. Shah et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants

Hongmei Nan et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Add to Collection

Article Medicine, General & Internal

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens et al.

LANCET (2015)

Add to Collection

Article Oncology

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch-Becker et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

Christos S. Karapetis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

T Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Multidisciplinary Sciences

Mutations of the BRAF gene in human cancer

H Davies et al.

NATURE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.